Biogen Inc. (BIIB) Social Stream
Biogen Inc (BIIB) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering BIIB.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-28 | 27 | $502 | $259 | $368.074 | $210.65 | 74.73% |
| 2021-11-19 | 27 | $502 | $209 | $364.321 | $210.65 | 72.95% |
| 2021-11-30 | 27 | $502 | $209 | $362.607 | $210.65 | 72.14% |
| 2021-12-08 | 27 | $502 | $209 | $359.448 | $210.65 | 70.64% |
| 2021-12-09 | 28 | $502 | $209 | $355.8 | $210.65 | 68.91% |
| 2021-12-21 | 28 | $502 | $209 | $352.344 | $210.65 | 67.27% |
| 2021-12-22 | 28 | $502 | $209 | $341.466 | $210.65 | 62.1% |
| 2021-12-23 | 28 | $502 | $209 | $340.133 | $210.65 | 61.47% |
| 2022-01-07 | 28 | $500 | $209 | $332.266 | $210.65 | 57.73% |
| 2022-01-13 | 29 | $500 | $195 | $316.548 | $210.65 | 50.27% |
| 2022-01-14 | 29 | $500 | $195 | $315.58 | $210.65 | 49.81% |
| 2022-01-18 | 29 | $500 | $195 | $309.709 | $210.65 | 47.03% |
| 2022-01-28 | 30 | $500 | $195 | $305.129 | $210.65 | 44.85% |
| 2022-02-02 | 29 | $500 | $195 | $305.129 | $210.65 | 44.85% |
| 2022-02-04 | 30 | $500 | $185 | $299.483 | $210.65 | 42.17% |
| 2022-02-08 | 30 | $500 | $185 | $287.1 | $210.65 | 36.29% |
| 2022-02-15 | 30 | $500 | $185 | $286.333 | $210.65 | 35.93% |
| 2022-02-25 | 30 | $500 | $185 | $286.066 | $210.65 | 35.8% |
| 2022-03-03 | 30 | $500 | $185 | $286.766 | $210.65 | 36.13% |
| 2022-03-08 | 30 | $500 | $185 | $284.066 | $210.65 | 34.85% |
| 2022-03-11 | 30 | $500 | $185 | $284.3 | $210.65 | 34.96% |
| 2022-03-28 | 30 | $500 | $185 | $284.133 | $210.65 | 34.88% |
| 2022-03-31 | 29 | $500 | $185 | $287 | $210.65 | 36.24% |
The Trend in the Analyst Price Target
BIIB's average price target has moved down $32.96 over the prior 22 months.
BIIB reports an average of 30.83% for its upside potential over the past 51 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-07-24 | 33 | 647 | 244.0 | 407.930 | 325.40 | 25.36% |
| 2021-08-07 | 33 | 647 | 279.1 | 414.420 | 340.00 | 21.89% |
| 2022-01-18 | 30 | 500 | 195.0 | 309.612 | 233.81 | 32.42% |
| 2022-02-02 | 29 | 500 | 195.0 | 305.129 | 224.96 | 35.64% |
| 2022-03-31 | 29 | 500 | 185.0 | 287.000 | 210.60 | 36.28% |
BIIB Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.19 | 10 | 3 | 16 | 0 | 0 | 29 |
The Trend in the Broker Recommendations
Over the past 20 months, BIIB's average broker recommendation rating improved by 0.49.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how Biogen Inc fares relative to all US stocks, note that its number of analysts covering the stock is greater than 2591.36% of that group.
- BIIB has a higher average analyst price target than 2549.76% of Pharmaceutical Products stocks.
- In the context of stocks in the large market cap category, Biogen Inc's variance in analysts' estimates is lower than -2271.73% of them.
- In the context of Pharmaceutical Products stocks, Biogen Inc's upside potential (average analyst target price relative to current price) is higher than 577.25% of them.
In the Pharmaceutical Products industry, ARGX, AMGN, and TLRY are the three stocks most similar to Biogen Inc regarding the price target and analyst recommendation information presented here.
What is the outlook for BIIB? Use POWR Ratings for clearer insight into price direction.